Leerink Partnrs Weighs in on ORKA FY2028 Earnings

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Research analysts at Leerink Partnrs issued their FY2028 earnings per share estimates for shares of Oruka Therapeutics in a research report issued to clients and investors on Wednesday, November 13th. Leerink Partnrs analyst D. Risinger expects that the company will post earnings of ($2.92) per share for the year. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($1.69) per share.

A number of other research analysts have also commented on ORKA. Lifesci Capital started coverage on Oruka Therapeutics in a research report on Monday, September 16th. They issued an “outperform” rating and a $41.00 price objective on the stock. Wedbush began coverage on Oruka Therapeutics in a report on Wednesday, September 4th. They set an “outperform” rating and a $40.00 price objective on the stock. TD Cowen assumed coverage on shares of Oruka Therapeutics in a research note on Monday, September 16th. They issued a “buy” rating for the company. Jefferies Financial Group assumed coverage on shares of Oruka Therapeutics in a report on Friday, September 13th. They issued a “buy” rating and a $40.00 price objective on the stock. Finally, Leerink Partners assumed coverage on Oruka Therapeutics in a research note on Tuesday, September 17th. They issued an “outperform” rating and a $44.00 price target for the company. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $43.17.

Oruka Therapeutics Stock Performance

Shares of ORKA opened at $24.00 on Friday. The stock has a 50 day simple moving average of $26.78. Oruka Therapeutics has a one year low of $18.72 and a one year high of $53.88.

Institutional Investors Weigh In On Oruka Therapeutics

A number of institutional investors have recently made changes to their positions in ORKA. Braidwell LP bought a new position in shares of Oruka Therapeutics during the third quarter worth approximately $12,640,000. Great Point Partners LLC bought a new stake in shares of Oruka Therapeutics during the 3rd quarter worth $12,614,000. FMR LLC acquired a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at approximately $114,763,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Oruka Therapeutics during the third quarter worth $1,037,000. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.